Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women's health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface proteins, COVID-19 RT-PCR kit, and COVID-19 Variant RT-qPCR kit, as well as MPXV real time PCR kit, a real-time polymerase chain reaction assay for the qualitative detection of nucleic acid from Monkeypox virus. In addition, it offers diagnostic equipment, such as urinalysis, blood glucose meters, and immunodiagnostics tools. Further, it provides other test kits, such as Cotinine to test cotinine in urine; and G6PD, an in vitro diagnostic test that can detect glucose-6-phosphate dehydrogenase in human whole blood. The company was founded in 2000 and is headquartered in Anyang-si, South Korea.
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is reasonably priced on P/FCF.